drugset / Trial / NCT04909892
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b study to assess the safety and efficacy of COVI-MSC in treating post COVID-19 "long haulers" with pulmonary compromise.
Timeline
- Start
- 2021-08
- Primary completion
- 2022-01
- Completion
- 2022-01
Outcome
Outcome not reported
Stopped: “Replaced by a different protocol.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVI-MSC | Cell therapy | 18.5 cells | Intravenous |
| Subject | COVI-MSC | Cell therapy | 37 cells | Intravenous |